Development of cataplasmic transdermal drug delivery system containing eutectic mixture of lidocaine and prilocaine

被引：18

作者：

Chun M.-K. ^{[1
]}

Hossain K. ^{[1
]}

Choi S.-H. ^{[1
]}

Ban S.-J. ^{[1
]}

Moon H. ^{[1
]}

Choi H.-K. ^{[1
]}

机构：

[1] BK21 Project Team, College of Pharmacy, Chosun University, Dong-gu, Gwangju, 501-759

来源：

Journal of Pharmaceutical Investigation | 2012年 / 42卷 / 3期

关键词：

Cataplasm; Eutectic mixture; Lidocaine; Prilocaine; Transdermal drug delivery system;

D O I：

10.1007/s40005-012-0023-6

中图分类号：

学科分类号：

摘要：

A novel transdermal drug delivery system with the eutectic mixture of lidocaine and prilocaine was developed. The permeation of lidocaine and prilocaine proportionally increased as the weight ratio of poly(vinyl alcohol) to poly(acrylic acid) changed from 1:1 to 7:1. However, the adhesive property of the matrix significantly degraded over the ratio of 5:1. The incorporation of humectants in the matrix had a noticeable effect on the permeation of lidocaine and prilocaine. The flux of lidocaine increased as the ratio of lidocaine in the eutectic mixture increased. The permeation rate decreased significantly from the cataplasm containing 3. 5:1 and 4:1 ratio of lidocaine to prilocaine due to recrystallization. When total drug concentration of the cataplasm with the ratio of 3:1 increased from 1. 33 to 4 % against adhesive gel weight, the permeation of both lidocaine and prilocaine increased. However, crystallization was observed beyond 2. 66 % w/w of combined drug load. Enhancers were not effective in the present study as most of the enhancer showed very low or no enhancement effect. No significant changes in the appearance and the drug content in the cataplasm were observed for 3 months. © 2012 The Korean Society of Pharmaceutical Sciences and Technology.

引用

页码：139 / 146

页数：7

共 22 条

[1]

Agarwal V., Singh S.K., Reddy I.K., Durrani M.J., Khan M.A., Cataplasm-based controlled drug delivery: development and optimization of a novel formulation, Drug Dev Ind Pharm, 25, pp. 659-665, (1999)

[2]

Brodin A., Nyqvist-Mayer A., Wadsten T., Forslund B., Broberg F., Phase diagram and aqueous solubility of the lidocaine-prilocaine binary system, J Pharm Sci, 73, pp. 481-484, (1984)

[3]

Brunton L.L., Lazo J.S., Parker K.L., Goodman & Gilman's the Pharmacological Basis of Therapeutics, pp. 380-383, (2005)

[4]

Choi H.K., Angello J.T., The mathematical analysis and optimization of a flow through diffusion cell system, Pharm Res, 11, pp. 595-599, (1994)

[5]

Duncan P.G., Kobrinsky N., Prilocaine-induced methemoglobinemia in a newborn infant, Anesthesiology, 59, pp. 75-76, (1983)

[6]

Dworkin R.H., Schmader K.E., Treatment and prevention of postherpetic neuralgia, Clin Infect Dis, 36, pp. 877-882, (2003)

[7]

Fiala S., Brown M.B., Jones S.A., An investigation into the influence of binary drug solutions upon diffusion and partition processes in model membranes, J Pharm Pharmacol, 60, pp. 1615-1623, (2008)

[8]

Galer B.S., Rowbotham M.C., Perander J., Friedman E., Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study, Pain, 80, pp. 533-538, (1999)

[9]

Hossain M.K., Subedi R.K., Chun M.K., Kim E.J., Moon H.S., Choi H.K., Formulation and in vitro evaluation of transdermal drug delivery system for galantamine, J Pharm Invest, 41, pp. 1-7, (2011)

[10]

Ito K., Usuki M., Aimiya R., Cataplasm base and cataplasm using the same, (2006)

← 1 2 3 →